Voices
Ahmet Dirican: Real-World Data Discontinuation of Immunotherapy at 24 months in Metastatic NSCLC
Ahmet Dirican/X

Ahmet Dirican: Real-World Data Discontinuation of Immunotherapy at 24 months in Metastatic NSCLC

Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:

“I-STOP study |

Real-World Data Discontinuation of immunotherapy at 24 months in metastatic NSCLC:

  • No impact on OS (HR 1.22, p=0.66)
  • Higher risk of progression (HR 2.16, p=0.035)

Who may be at higher risk if treatment is stopped?

  • PD-L1 ≤50%
  • Brain metastases
  • ECOG PS ≥1
  • KRAS mutations

ICI rechallenge response rate: 62.5% Stopping at 2 years appears safe for many patients. However, biological risk stratification remains essential.”

Title: Real-World Outcomes of Immunotherapy Discontinuation at Two Years in Advanced Non-Small Cell Lung Cancer: final results of the ISTOP study.

Authors: Maria Gemelli, Luca Sala, Alessandro Morabito, Vincenzo Sforza, Alessio Cortellini, Giulia La Cava, Federica Bertolini, Giorgia Guaitoli, Simona Carnio, Silvia Novello, Alessandro Leonetti, Marcello Tiseo, Francesca Mazzoni, Federica Cosso, Marianna Macerelli, Alexandro Membrino, Giulio Metro, Rita Chiari, Carlo Genova, Rossana Berardi, Elena Tassi, Laura Antolini, Diego Luigi Cortinovis

Read the full article on European Journal of Cancer.

Ahmet Dirican: Real-World Data Discontinuation of Immunotherapy at 24 months in Metastatic NSCLC

More featuring Ahmet Dirican on OncoDaily.

Ahmet Dirican Alessandro Leonetti Alessandro Morabito Alessio Cortellini Alexandro Membrino cancer Carlo Genova Diego Luigi Cortinovis Elena Tassi Federica Bertolini Federica Cosso Francesca Mazzoni Giorgia Guaitoli Giulia La Cava Giulio Metro Laura Antolini Luca Sala Marcello Tiseo Maria Gemelli Marianna Macerelli NSCLC OncoDaily Oncology Rita Chiari Rossana Berardi Silvia Novello Simona Carnio Vincenzo Sforza